Ask AI

CELMoDs on the Horizon: A New Chapter in Lymphoma Care

Podcast
This activity is available for 0.50 CME/CE credit(s).

Released: August 25, 2026

Expiration: February 24, 2027

See Activity Collection

In this podcast, 2 experts explore the evolving role of CELMoD-based strategies in lymphoma, with a focus on the biologic mechanisms and emerging clinical evidence for golcadomide in diffuse large B-cell lymphoma and follicular lymphoma. Listeners will hear how CELMoDs differ from established immunomodulatory and immune-based therapies, review evidence from ongoing and early-phase studies of golcadomide as monotherapy and in combination regimens, and consider practice-relevant issues including efficacy, toxicity, treatment sequencing, combination strategies, and the experts’ thoughts on how emerging CELMoD therapy can be adopted into community-based lymphoma care.

CELMoDs in Lymphoma

Pre Assessment

Assess your current knowledge and clinical approach before beginning your podcast.
1.

How many people with lymphoma do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Which of the following best describes the biological rationale for CELMoD agents vs immunomodulatory drugs as a lymphoma treatment strategy?

How confident are you in your answer?
4.

You are educating your team about golcadomide in preparation for managing patients who may be treated with this agent. Which of the following adverse events associated with this novel agent will you highlight for them as important to monitor? 

How confident are you in your answer?